NCT05400317View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of AD-218

PHASE3RecruitingINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

July 27, 2022

Primary Completion Date

March 31, 2026

Study Completion Date

June 30, 2026

Conditions

Mixed Dyslipidemia

Interventions

DRUG

AD-218

PO, Once daily(QD), 12weeks

DRUG

AD-218A

PO, Once daily(QD), 12weeks

Trial Locations (1)

42415

RECRUITING

Yeongnam University Hospital, Daegu

All Listed Sponsors

lead

Addpharma Inc.

INDUSTRY